logo
  

Inovio's COVID-19 DNA Vaccine Candidate Safe And Well-tolerated In Phase 2 Trial

Inovio Pharmaceuticals Inc.'s (INO) DNA vaccine candidate for COVID-19, INO-4800, was generally safe, well-tolerated and immunogenic in all studied age groups, as per a phase 2 segment of its phase 2/3 clinical trial.

In Monday pre-market trade, INO was trading at $7.07, up $0.22 or 3.21 percent.

The phase 2 segment of its phase 2/3 clinical trial in the U.S., called INNOVATE, was designed to evaluate the safety, tolerability and immunogenicity of INO-4800 in a two-dose regimen (1.0 mg or 2.0 mg) in a three-to-one-randomization to receive either INO-4800 or placebo for each dose to identify optimal dose(s) for two age groups (18-50 years and 51 years and older) for the subsequent Phase 3 efficacy evaluation.

The Phase 2 segment of the trial enrolled about 400 participants, 18 years of age or older, at 16 U.S. sites.

The majority of adverse events were Grade 1 and Grade 2 in severity and did not appear to increase in frequency with the second dose. The number of participants experiencing each of the most common AEs did not differ between the two dosing groups.

The geometric mean fold rise (GMFR) of binding and neutralizing antibody levels were statistically significantly greater in the 2.0 mg dose group versus the 1.0 mg dose group.

According to the preliminary results, the T cell immune responses measured by the ELISpot assay were also higher in the 2.0 mg dose group compared to the 1.0 mg dose group.

INOVIO plans to file preliminary Phase 2 results and device data with the U.S. Food and Drug Administration. The company plans to conduct a global Phase 3 clinical trial for INO-4800. The company has selected 2.0 mg dose for the phase 3 segment of the trial.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Department store chain Sears is closing down its last store located in its home state of Illinois, CNBC reported. The company, which was founded in Chicago in 1892, plans to shut the shop, located in Simon Property Group's Woodfield Mall, on November 14. Sears' parent company, Transformco, which also manages the real estate, said it plans to maximize the value of the Woodfield Mall property and Amazon said over 1 million people have applied for a job at the tech major as part of its Career Day 2021. Job seekers from more than 170 countries have participated in the virtual event. In addition, more than 2,000 Amazon recruiters offered 30,000 individual career coaching sessions with participants in a single day.
Follow RTT